UCB SA
UCB
Company Profile
Business description
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).
Contact
Allee de la Recherche, 60
BrusselsB-1070
BELT: +32 25599999
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
9,378
Stocks News & Analysis
stocks
3 global ‘buy the dip’ candidates with wide moats
Does recent share price weakness spell opportunity in these three high-quality companies? Our analysts think so.
stocks
What next for Nine Entertainment after Domain payout?
The media group has excelled in controlling what it can control. Now the focus shifts to capital deployment.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,132.80 | 22.20 | 0.24% |
| CAC 40 | 7,823.52 | 62.20 | 0.80% |
| DAX 40 | 23,703.65 | 70.70 | 0.30% |
| Dow JONES (US) | 46,108.00 | 617.08 | 1.36% |
| FTSE 100 | 9,297.58 | 72.19 | 0.78% |
| HKSE | 26,484.19 | 397.87 | 1.53% |
| NASDAQ | 22,043.07 | 157.01 | 0.72% |
| Nikkei 225 | 44,806.83 | 434.33 | 0.98% |
| NZX 50 Index | 13,223.83 | 5.32 | -0.04% |
| S&P 500 | 6,587.47 | 55.43 | 0.85% |
| S&P/ASX 200 | 8,868.50 | 25.60 | 0.29% |
| SSE Composite Index | 3,885.87 | 10.56 | 0.27% |